@prefix dbo: .
@prefix dbr: .
dbr:Tamoxifen dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Bimatoprost dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pemoline dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Clascoterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Gestrinone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nabilone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Apremilast dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Levomilnacipran dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Alectinib dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cysteinyl-leukotriene_type_1_receptor_antagonists dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ixazomib dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Segesterone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Equilin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Plasma_protein_bound dbo:wikiPageWikiLink dbr:Plasma_protein_binding ;
dbo:wikiPageRedirects dbr:Plasma_protein_binding .
dbr:Doxepin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Clomipramine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Tricyclic_antidepressant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Amitriptyline dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Fluvastatin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Levamlodipine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
@prefix foaf: .
@prefix wikipedia-en: .
wikipedia-en:Plasma_protein_binding foaf:primaryTopic dbr:Plasma_protein_binding .
dbr:Bremelanotide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dopamine_agonist dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Tibolone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Raloxifene dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Quinolone_antibiotic dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Linezolid dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Topical_prednisolone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Megestrol_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Abiraterone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Suvorexant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ethinylestradiol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Norethisterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Carvedilol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Desogestrel dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Relugolix dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Valbenazine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Viloxazine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Enzalutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Gestodene dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nafarelin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Apalutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Lynestrenol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Toremifene dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Trazodone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Daridorexant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Allopregnanolone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cyproterone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Danazol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Etonogestrel dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nitazoxanide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nomegestrol_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Lemborexant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Iprindole dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dibenzepin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Diethylstilbestrol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nefopam dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Opipramol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ethylene_glycol_poisoning dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Phenobarbital dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Testosterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Estrogen dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Levonorgestrel dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Quetiapine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Eslicarbazepine_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Bcr-Abl_tyrosine-kinase_inhibitor dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dydrogesterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dienogest dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Valproate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Bicalutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacokinetics_of_testosterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacology_of_bicalutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Elagolix dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Drospirenone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Estramustine_phosphate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pregabalin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacodynamics_of_progesterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacokinetics_of_estradiol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacology_of_cyproterone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Vortioxetine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Melatonin_as_a_medication_and_supplement dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Fulvestrant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Gabapentinoid dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Androstanolone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cetirizine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Darolutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dihydrotestosterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Mianserin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nefazodone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Biological_half-life dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Oclacitinib dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Buserelin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Butriptyline dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Trimegestone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Brivudine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Naltrexone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Noretynodrel dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Verapamil dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Methyltestosterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Metformin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Medroxyprogesterone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ketanserin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Butizide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pimobendan dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Hydrocodone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Oxandrolone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Hydrocortisone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
@prefix rdfs: .
dbr:Plasma_protein_binding rdfs:label "Proteinbindung"@de ,
"Plasma protein binding"@en ,
"Uni\u00F3 a prote\u00EFnes plasm\u00E0tiques"@ca ,
"\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u7D50\u5408"@ja ,
"\u0421\u0432\u044F\u0437\u044B\u0432\u0430\u043D\u0438\u0435 \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043F\u043B\u0430\u0437\u043C\u044B"@ru ,
"Liga\u00E7\u00E3o a prote\u00EDnas plasm\u00E1ticas"@pt ,
"Uni\u00F3n a prote\u00EDna plasm\u00E1tica"@es ,
"Legame dei farmaci alle proteine plasmatiche"@it ,
"Ikatan protein plasma"@in ,
"\u0631\u0628\u0637 \u0628\u0631\u0648\u062A\u064A\u0646\u064A"@ar ,
"\u8840\u6D46\u86CB\u767D\u7ED3\u5408"@zh ,
"Plasma-eiwitbinding"@nl ;
rdfs:comment "L'efic\u00E0cia d'un f\u00E0rmac pot ser afectada pel grau d'uni\u00F3 a les prote\u00EFnes dins del plasma sanguini. Es tracta de la m\u00EDnima part unida d'un f\u00E0rmac que pot travessar de manera eficient les membranes cel\u00B7lulars o difondre's. Les prote\u00EFnes comunes a les quals s'uneix un f\u00E0rmac s\u00F3n l'alb\u00FAmina serosa humana, les lipoprote\u00EFnes, glicoprote\u00EFnes \u03B1, \u00DF, i les \u03B3 . Prote\u00EFna + f\u00E0rmac \u21CC Complex F\u00E0rmac-Prote\u00EFna"@ca ,
"\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u7D50\u5408\uFF08\u3051\u3063\u3057\u3087\u3046\u30BF\u30F3\u30D1\u30AF\u3051\u3064\u3054\u3046\uFF09\u306F\u3001\u85AC\u7269\u3068\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u306E\u9593\u306E\u7D50\u5408\u3002 \u85AC\u7269\u306E\u52B9\u679C\u306F\u3001\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u3057\u3084\u3059\u3055\u306B\u5F71\u97FF\u3092\u53D7\u3051\u308B\u3002\u3088\u308A\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u304C\u5F31\u3044\u85AC\u7269\u306F\u3088\u308A\u52B9\u7387\u3088\u304F\u7D30\u80DE\u819C\u3092\u900F\u904E\u3057\u7D44\u7E54\u4E2D\u306B\u62E1\u6563\u3059\u308B\u3002\u85AC\u7269\u3068\u7D50\u5408\u3092\u6210\u3059\u4EE3\u8868\u7684\u306A\u8840\u4E2D\u30BF\u30F3\u30D1\u30AF\u8CEA\u306B\u306F\u8840\u6E05\u30A2\u30EB\u30D6\u30DF\u30F3\u3001\u30EA\u30DD\u30BF\u30F3\u30D1\u30AF\u8CEA\u3001\u7CD6\u30BF\u30F3\u30D1\u30AF\u8CEA\u3001\u3068\u03B1\u3001\u03B2\u3001\u03B3\u306E\u5404\u30B0\u30ED\u30D6\u30EA\u30F3\u3067\u3042\u308B\u3002 \u85AC\u7269\u306F\u8840\u4E2D\u3067\u306F\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u306B\u7D50\u5408\u3057\u3066\u3044\u308B\u7D50\u5408\u578B\u3001\u7D50\u5408\u3057\u3066\u3044\u306A\u3044\u975E\u7D50\u5408\u578B\u306E\u4E8C\u3064\u306E\u72B6\u614B\u3067\u5B58\u5728\u3059\u308B\u3002\u7D50\u5408\u578B\u3068\u975E\u7D50\u5408\u578B\u306E\u5B58\u5728\u6BD4\u7387\u306F\u3001\u901A\u5E38\u306F\u5404\u85AC\u7269\u306B\u56FA\u6709\u306A\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u89AA\u548C\u6027\u306B\u3088\u308A\u6C7A\u5B9A\u3055\u308C\u308B\u3002\u307B\u3068\u3093\u3069\u306E\u533B\u85AC\u54C1\u306F\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u304C\u53EF\u9006\u3067\u3042\u308A\u3001\u4EE5\u4E0B\u306E\u3088\u3046\u306A\u5316\u5B66\u5E73\u8861\u304C\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\uFF08P\uFF09\u3001\u7D50\u5408\u578B\uFF08PD complex\uFF09\u3001\u975E\u7D50\u5408\u578B\uFF08D\uFF09\u306E\u9593\u306B\u6210\u308A\u7ACB\u3064\u3002"@ja ,
"\u0627\u0644\u0631\u0628\u0637 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u064A \u0644\u0647 \u0623\u0647\u0645\u064A\u0629 \u0641\u064A \u0639\u0644\u0648\u0645 \u0627\u0644\u0635\u064A\u062F\u0644\u0629 \u0648\u0627\u0644\u0637\u0628\u060C \u0641\u0642\u062F \u062A\u062A\u0623\u062B\u0631 \u0643\u0641\u0627\u0621\u0629 \u0627\u0644\u062F\u0648\u0627\u0621 \u0628\u0627\u0644\u062F\u0631\u062C\u0629 \u0627\u0644\u062A\u064A \u062A\u062A\u0631\u0628\u0637 \u0628\u0647\u0627 \u0628\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0628\u0644\u0627\u0632\u0645\u0627 \u0627\u0644\u062F\u0645. \u0623\u0642\u0644 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0631\u062A\u0628\u0627\u0637\u0627\u064B \u0628\u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0647\u064A \u0623\u0643\u062B\u0631\u0647\u0627 \u0643\u0641\u0627\u0621\u0629 \u0648\u064A\u0645\u0643\u0646\u0647\u0627 \u0623\u0646 \u062A\u0639\u0628\u0631 \u0627\u0644\u0623\u063A\u0634\u064A\u0629 \u0627\u0644\u062E\u0644\u0648\u064A\u0629 \u0648\u062A\u0646\u062A\u0634\u0631. \u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0627\u0644\u062F\u0645 \u0627\u0644\u0634\u0627\u0626\u0639\u0629 \u0627\u0644\u062A\u064A \u062A\u0631\u062A\u0628\u0637 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0628\u0647\u0627 \u0647\u064A: \n* \u0623\u0644\u0628\u064A\u0648\u0645\u064A\u0646 \u0627\u0644\u0645\u0635\u0644 \u0627\u0644\u0628\u0634\u0631\u064A \n* \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u062F\u0647\u0646\u064A \n* \u0628\u0631\u0648\u062A\u064A\u0646 \u0633\u0643\u0631\u064A \n* \u063A\u0644\u0648\u0628\u0648\u0644\u064A\u0646 \n* \n* \n* \n* \u063A\u0644\u0648\u0628\u064A\u0648\u0644\u064A\u0646 \u063A\u0627\u0645\u0627 \u0628\u0631\u0648\u062A\u064A\u0646 + \u062F\u0648\u0627\u0621 \u21CC \u0645\u0639\u0642\u062F \u0628\u0631\u0648\u062A\u064A\u0646-\u062F\u0648\u0627\u0621"@ar ,
"La eficacia de un f\u00E1rmaco puede ser afectada por el grado de uni\u00F3n a las prote\u00EDnas dentro del plasma sangu\u00EDneo. La m\u00EDnima parte unida de un f\u00E1rmaco puede atravesar de manera eficiente las membranas celulares o difundirse. Las prote\u00EDnas comunes a las cuales se une un f\u00E1rmaco son la alb\u00FAmina s\u00E9rica humana, las lipoprote\u00EDnas, glicoprote\u00EDnas \u03B1, \u00DF\u201A y a las \u03B3 globulinas. Prote\u00EDna + f\u00E1rmaco \u21CC Complejo F\u00E1rmaco-Prote\u00EDna"@es ,
"As drogas sofrem liga\u00E7\u00E3o a prote\u00EDnas plasm\u00E1ticas. A efic\u00E1cia de uma droga \u00E9 afetada pelo grau em que ela se liga a prote\u00EDnas no plasma sangu\u00EDneo. Quanto menos ligante a droga for, mais eficientemente ela pode transpor as membranas celular ou se difundir. As prote\u00EDnas em que as drogas mais se ligam s\u00E3o a albumina, lipoprote\u00EDna, glicoprote\u00EDna e globulinas \u03B1, \u00DF\u201A e \u03B3. prote\u00EDna + droga \u21CC complexo prote\u00EDna-droga"@pt ,
"Il legame dei farmaci alle proteine plasmatiche \u00E8 il parametro farmacocinetico pi\u00F9 importante nel determinare la ripartizione di un farmaco dal sangue ai tessuti.Tale fenomeno consiste nella creazione di legami deboli e reversibili tra un farmaco e uno specifico sito di una proteina plasmatica."@it ,
"Ikatan protein plasma merujuk pada sejauh mana sebuah obat terikat pada protein di dalam darah. Semakin sedikit ikatan suatu obat, semakin efisien obat tersebut dapat melintasi membran sel atau berdifusi. Protein di dalam darah yang mengikat obat antara lain albumin serum, lipoprotein, glikoprotein, dan globulin alfa, beta, serta gamma."@in ,
"\u0414\u043B\u044F \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u043E\u0432, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u0434\u043E\u043B\u0436\u043D\u044B \u0440\u0430\u0441\u043F\u0440\u043E\u0441\u0442\u0440\u0430\u043D\u044F\u0442\u044C\u0441\u044F \u043F\u043E \u0442\u0435\u043B\u0443 \u0447\u0435\u0440\u0435\u0437 \u043A\u0440\u043E\u0432\u044C, \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C \u043C\u043E\u0436\u0435\u0442 \u0437\u0430\u0432\u0438\u0441\u0435\u0442\u044C \u043E\u0442 \u0441\u0442\u0435\u043F\u0435\u043D\u0438 \u0435\u0433\u043E \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u043D\u0438\u044F \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043F\u043B\u0430\u0437\u043C\u044B \u043A\u0440\u043E\u0432\u0438. \u0427\u0435\u043C \u043C\u0435\u043D\u044C\u0448\u0435 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u0435\u0442\u0441\u044F, \u0442\u0435\u043C \u0431\u043E\u043B\u044C\u0448\u0438\u0439 \u043E\u043D \u043E\u043A\u0430\u0437\u044B\u0432\u0430\u0435\u0442 \u044D\u0444\u0444\u0435\u043A\u0442. \u041E\u0441\u043D\u043E\u0432\u043D\u044B\u043C\u0438 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043A\u0440\u043E\u0432\u0438, \u0441 \u043A\u043E\u0442\u043E\u0440\u044B\u043C\u0438 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u044E\u0442\u0441\u044F \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430, \u044F\u0432\u043B\u044F\u044E\u0442\u0441\u044F \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D\u044B, \u043B\u0438\u043F\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u044B, \u0433\u043B\u0438\u043A\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u044B \u0438 \u0433\u043B\u043E\u0431\u0443\u043B\u0438\u043D\u044B (\u03B1, \u03B2, \u03B3). \u0411\u0435\u043B\u043A\u0438 + \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430 \u21CC \u043A\u043E\u043C\u043F\u043B\u0435\u043A\u0441 \u0431\u0435\u043B\u043E\u043A-\u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u043E"@ru ,
"\u5927\u591A\u6570\u836F\u7269\u53EF\u4EE5\u4E0E\u8840\u6D46\u4E2D\u7684\u86CB\u767D\u8D28(\u5982\u4EBA\u8840\u6E05\u767D\u86CB\u767D\u3001\u8102\u86CB\u767D\u3001\u7CD6\u86CB\u767D\u548C\u03B1, \u03B2, \u03B3 \u7403\u86CB\u767D)\u53D1\u751F\u4E0D\u540C\u7A0B\u5EA6\u7684\u7ED3\u5408\u3002\u5F31\u9178\u6027\u836F\u7269\u4E3B\u8981\u4E0E\u767D\u86CB\u767D\u7ED3\u5408\uFF0C\u5F31\u78B1\u6027\u836F\u7269\u9664\u4E86\u4E0E\u767D\u86CB\u767D\u7ED3\u5408\u5916\uFF0C\u8FD8\u5E38\u4E0E\u8102\u86CB\u767D\u3001\u9178\u6027\u7CD6\u86CB\u767D\u7ED3\u5408\u3002 \u836F\u7269\u4E0E\u8840\u6D46\u86CB\u767D\u7684\u7ED3\u5408\u5F71\u54CD\u836F\u7269\u7684\u6269\u6563\u901F\u5EA6\u3001\u8F6C\u8FD0\u901F\u5EA6\u3001\u4F5C\u7528\u5F3A\u5EA6\u548C\u6D88\u9664\u901F\u7387\u3002 \u836F\u7269\u4E0E\u8840\u6D46\u86CB\u767D\u7684\u7ED3\u5408\u4F53(\u53C8\u79F0)\u4E0D\u80FD\u7A7F\u8FC7\u8840\u7BA1\u5185\u76AE\u7EC6\u80DE\uFF0C\u4E0D\u80FD\u53D1\u6325\u836F\u6548\uFF0C\u56E0\u6B64\u8FD9\u79CD\u7ED3\u5408\u6210\u4E3A\u836F\u7269\u5728\u8840\u6DB2\u4E2D\u7684\u4E00\u79CD\u6682\u65F6\u8D2E\u5B58\u5F62\u5F0F\u3002\u53C8\u56E0\u4E3A\u8FD9\u79CD\u7ED3\u5408\u662F\u53EF\u9006\u7684\uFF0C\u5F53\u8840\u6D46\u4E2D\u6E38\u79BB\u578B\u7684\u836F\u7269\u56E0\u6269\u6563\u3001\u6E05\u9664\u800C\u6D53\u5EA6\u964D\u4F4E\u65F6\uFF0C\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7684\u836F\u7269\u5C31\u4F1A\u6E38\u79BB\u51FA\u6765\uFF0C\u6269\u6563\u5165\u7EC4\u7EC7\u4E2D\u53D1\u6325\u836F\u6548\u3002\u53C8\u56E0\u4E3A\u8FD9\u79CD\u7ED3\u5408\u6CA1\u6709\u7279\u5F02\u6027\uFF0C\u5F53\u4E24\u79CD\u836F\u7269\u5B58\u5728\u4E8E\u8840\u6DB2\u4E2D\u65F6\uFF0C\u4E24\u8005\u53EF\u56E0\u7ADE\u4E89\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7684\u4F4D\u7F6E\uFF0C\u63D0\u9AD8\u836F\u7269\u5728\u8840\u6D46\u4E2D\u7684\u6E38\u79BB\u6D53\u5EA6\uFF0C\u52A0\u901F\u5176\u6269\u6563\uFF0C\u63D0\u9AD8\u5176\u836F\u6548\uFF0C\u540C\u65F6\u52A0\u91CD\u5176\u526F\u4F5C\u7528\u3002 \u4E00\u822C\u8BA4\u4E3A\uFF0C\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7387\u9AD8\u3001\u5206\u5E03\u5BB9\u79EF\u5C0F\u3001\u6D88\u9664\u6162\u3001\u6CBB\u7597\u6307\u6570\u4F4E\u7684\u836F\u7269\uFF0C\u5BB9\u6613\u51FA\u73B0\u4E0A\u8FF0\u7684\u836F\u7269\u76F8\u4E92\u4F5C\u7528\u3002 \u6BD4\u5982\u6297\u51DD\u8840\u836F\u534E\u6CD5\u6797(warfarin)99%\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\uFF0C\u5F53\u5B83\u4E0E\u4FDD\u6CF0\u677E(\uFF0C\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u738798%)\u5408\u7528\u65F6\uFF0C\u7ED3\u5408\u7684\u534E\u6CD5\u6797\u4F1A\u88AB\u7F6E\u6362\u51FA\u6765\uFF0C\u6E38\u79BB\u578B\u7684\u534E\u6CD5\u6797\u6D53\u5EA6\u5347\u9AD8\uFF0C\u52A0\u5F3A\uFF0C\u52A0\u91CD\uFF0C\u60A3\u8005\u53EF\u56E0\u4E25\u91CD\u51FA\u8840\u800C\u6B7B\u4EA1\u3002"@zh ,
"De plasma-eiwitbinding is het gedeelte van een geneesmiddel of lichaamseigen stof dat aan plasma-eiwitten in het bloed is gebonden. Toegediende geneesmiddelen kunnen net als lichaamseigen stoffen zoals calcium met de aanwezige plasma-eiwitten een binding aangaan. Er is dan een gedeelte dat is gebonden aan plasma-eiwitten en er is een ongebonden, vrije fractie. Alleen het niet-gebonden gedeelte van het geneesmiddel is farmacologisch actief. Ook bij de omzetting in de lever en bij de eliminatie via de nieren wordt alleen de ongebonden fractie verwerkt. De gebonden fractie vormt zo een soort van reservoir van het geneesmiddel, dat weer vrij kan komen als de binding reversibel is."@nl ,
"Als Proteinbindung, auch Plasmaproteinbindung (PPB) oder Plasmaeiwei\u00DFbindung (PEB) genannt, wird die reversible Bindung von Stoffen an Eiwei\u00DFbestandteile des Blutes (Plasmaproteine, Erythrozytenproteine) oder der K\u00F6rpergewebe bezeichnet. An dieser Proteinbindung k\u00F6nnen verschiedene Formen chemischer Bindungen beteiligt sein, namentlich ionische Bindungen, Wasserstoffbr\u00FCckenbindungen, Dipol-Dipol-Wechselwirkungen sowie hydrophobe Wechselwirkungen. Die Proteinbindung hat zur Folge, dass die gebundenen Stoffe, unter anderem Arzneimittel und verschiedene k\u00F6rpereigene Substanzen, ihre normale Wirkung nicht oder nur vermindert aus\u00FCben, da sie nicht wie sonst mit der Umgebung reagieren k\u00F6nnen. Der durch Proteine gebundene Anteil eines Stoffes ist somit pharmakologisch inaktiv. Kleine Molek\u00FCle er"@de ,
"Plasma protein binding refers to the degree to which medications attach to proteins within the blood. A drug's efficiency may be affected by the degree to which it binds. The less bound a drug is, the more efficiently it can traverse or diffuse through cell membranes. Common blood proteins that drugs bind to are human serum albumin, lipoprotein, glycoprotein, and \u03B1, \u03B2\u201A and \u03B3 globulins."@en .
@prefix dcterms: .
@prefix dbc: .
dbr:Plasma_protein_binding dcterms:subject dbc:Pharmacokinetics ,
dbc:Biochemistry ;
dbo:abstract "\u0414\u043B\u044F \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u043E\u0432, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u0434\u043E\u043B\u0436\u043D\u044B \u0440\u0430\u0441\u043F\u0440\u043E\u0441\u0442\u0440\u0430\u043D\u044F\u0442\u044C\u0441\u044F \u043F\u043E \u0442\u0435\u043B\u0443 \u0447\u0435\u0440\u0435\u0437 \u043A\u0440\u043E\u0432\u044C, \u044D\u0444\u0444\u0435\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C \u043C\u043E\u0436\u0435\u0442 \u0437\u0430\u0432\u0438\u0441\u0435\u0442\u044C \u043E\u0442 \u0441\u0442\u0435\u043F\u0435\u043D\u0438 \u0435\u0433\u043E \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u043D\u0438\u044F \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043F\u043B\u0430\u0437\u043C\u044B \u043A\u0440\u043E\u0432\u0438. \u0427\u0435\u043C \u043C\u0435\u043D\u044C\u0448\u0435 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u0435\u0442\u0441\u044F, \u0442\u0435\u043C \u0431\u043E\u043B\u044C\u0448\u0438\u0439 \u043E\u043D \u043E\u043A\u0430\u0437\u044B\u0432\u0430\u0435\u0442 \u044D\u0444\u0444\u0435\u043A\u0442. \u041E\u0441\u043D\u043E\u0432\u043D\u044B\u043C\u0438 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043A\u0440\u043E\u0432\u0438, \u0441 \u043A\u043E\u0442\u043E\u0440\u044B\u043C\u0438 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u044E\u0442\u0441\u044F \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430, \u044F\u0432\u043B\u044F\u044E\u0442\u0441\u044F \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D\u044B, \u043B\u0438\u043F\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u044B, \u0433\u043B\u0438\u043A\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u044B \u0438 \u0433\u043B\u043E\u0431\u0443\u043B\u0438\u043D\u044B (\u03B1, \u03B2, \u03B3). \u041F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u044B \u043D\u0430\u0445\u043E\u0434\u044F\u0442\u0441\u044F \u0432 \u043A\u0440\u043E\u0432\u0438 \u0432 \u0434\u0432\u0443\u0445 \u0444\u043E\u0440\u043C\u0430\u0445: \u0441\u0432\u044F\u0437\u0430\u043D\u043D\u043E\u0439 \u0438 \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u043E\u0439. \u0412 \u0437\u0430\u0432\u0438\u0441\u0438\u043C\u043E\u0441\u0442\u0438 \u043E\u0442 \u0441\u0440\u043E\u0434\u0441\u0442\u0432\u0430 \u043A\u043E\u043D\u043A\u0440\u0435\u0442\u043D\u043E\u0433\u043E \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430 \u043A \u0431\u0435\u043B\u043A\u0430\u043C \u043F\u043B\u0430\u0437\u043C\u044B, \u0434\u043E\u043B\u044F \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430 \u043C\u043E\u0436\u0435\u0442 \u043F\u0435\u0440\u0435\u0439\u0442\u0438 \u0432 \u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0443\u044E \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043F\u043B\u0430\u0437\u043C\u044B \u0444\u043E\u0440\u043C\u0443, \u0430 \u043E\u0441\u0442\u0430\u0432\u0448\u0430\u044F\u0441\u044F \u0447\u0430\u0441\u0442\u044C \u043E\u0441\u0442\u0430\u043D\u0435\u0442\u0441\u044F \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u043E\u0439. \u0415\u0441\u043B\u0438 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u043D\u0438\u044F \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043E\u0431\u0440\u0430\u0442\u0438\u043C\u043E, \u0442\u043E \u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0438 \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0444\u043E\u0440\u043C\u044B \u0431\u0443\u0434\u0443\u0442 \u043D\u0430\u0445\u043E\u0434\u0438\u0442\u044C\u0441\u044F \u0432 \u0445\u0438\u043C\u0438\u0447\u0435\u0441\u043A\u043E\u043C \u0440\u0430\u0432\u043D\u043E\u0432\u0435\u0441\u0438\u0438 \u0442\u0430\u043A\u0438\u043C \u043E\u0431\u0440\u0430\u0437\u043E\u043C: \u0411\u0435\u043B\u043A\u0438 + \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430 \u21CC \u043A\u043E\u043C\u043F\u043B\u0435\u043A\u0441 \u0431\u0435\u043B\u043E\u043A-\u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u043E \u0418\u043C\u0435\u043D\u043D\u043E \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0434\u043E\u043B\u044F \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432\u0430 \u0431\u0443\u0434\u0435\u0442 \u043E\u043A\u0430\u0437\u044B\u0432\u0430\u0442\u044C \u0442\u0435\u0440\u0430\u043F\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043A\u0438\u0439 \u044D\u0444\u0444\u0435\u043A\u0442. \u0422\u0430\u043A\u0436\u0435 \u044D\u0442\u0430 \u0447\u0430\u0441\u0442\u044C \u043C\u043E\u0436\u0435\u0442 \u0431\u044B\u0442\u044C \u043F\u043E\u0434\u0432\u0435\u0440\u0433\u043D\u0443\u0442\u0430 \u0431\u0438\u043E\u0442\u0440\u0430\u043D\u0441\u0444\u043E\u0440\u043C\u0430\u0446\u0438\u0438 \u0438/\u0438\u043B\u0438 \u044D\u043B\u0438\u043C\u0438\u043D\u0430\u0446\u0438\u0438. \u041D\u0430\u043F\u0440\u0438\u043C\u0435\u0440, \u00AB\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0447\u0430\u0441\u0442\u044C\u00BB \u0430\u043D\u0442\u0438\u043A\u043E\u0430\u0433\u0443\u043B\u044F\u043D\u0442\u0430 \u0432\u0430\u0440\u0444\u0430\u0440\u0438\u043D\u0430 \u0441\u043E\u0441\u0442\u0430\u0432\u043B\u044F\u0435\u0442 97 %. \u042D\u0442\u043E \u043E\u0437\u043D\u0430\u0447\u0430\u0435\u0442, \u0447\u0442\u043E \u0438\u0437 \u0432\u0441\u0435\u0433\u043E \u0432\u0432\u0435\u0434\u0435\u043D\u043D\u043E\u0433\u043E \u0432 \u043E\u0440\u0433\u0430\u043D\u0438\u0437\u043C \u0432\u0430\u0440\u0444\u0430\u0440\u0438\u043D\u0430 , 97 % \u0441\u0432\u044F\u0437\u0430\u043D\u043E \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043A\u0440\u043E\u0432\u0438. \u041E\u0441\u0442\u0430\u0432\u0448\u0438\u0435\u0441\u044F 3 % (\u0447\u0430\u0441\u0442\u044C \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F) \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430 \u043F\u0440\u043E\u044F\u0432\u043B\u044F\u044E\u0442 \u0430\u043A\u0442\u0438\u0432\u043D\u043E\u0441\u0442\u044C \u0438 \u043C\u043E\u0433\u0443\u0442 \u0431\u044B\u0442\u044C \u0432\u044B\u0432\u0435\u0434\u0435\u043D\u044B. \u0421\u0432\u044F\u0437\u044B\u0432\u0430\u043D\u0438\u0435 \u0441 \u0431\u0435\u043B\u043A\u0430\u043C\u0438 \u043C\u043E\u0436\u0435\u0442 \u0432\u043B\u0438\u044F\u0442\u044C \u043D\u0430 \u043F\u0435\u0440\u0438\u043E\u0434 \u043F\u043E\u043B\u0443\u0432\u044B\u0432\u0435\u0434\u0435\u043D\u0438\u044F \u043B\u0435\u043A\u0430\u0440\u0441\u0442\u0432. \u0421\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0447\u0430\u0441\u0442\u044C \u0432\u044B\u0441\u0442\u0443\u043F\u0430\u0435\u0442 \u0432 \u043A\u0430\u0447\u0435\u0441\u0442\u0432\u0435 \u0440\u0435\u0437\u0435\u0440\u0432\u0443\u0430\u0440\u0430 \u0438\u043B\u0438 \u0434\u0435\u043F\u043E, \u0438\u0437 \u043A\u043E\u0442\u043E\u0440\u043E\u0433\u043E \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u043C\u0435\u0434\u043B\u0435\u043D\u043D\u043E \u0432\u044B\u0434\u0435\u043B\u044F\u0435\u0442\u0441\u044F \u0432 \u0432\u0438\u0434\u0435 \u0441\u0432\u043E\u0431\u043E\u0434\u043D\u043E\u0439 \u0444\u043E\u0440\u043C\u044B. \u0412 \u0442\u043E \u0432\u0440\u0435\u043C\u044F, \u043A\u0430\u043A \u043D\u0435\u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0447\u0430\u0441\u0442\u044C \u043C\u0435\u0442\u0430\u0431\u043E\u043B\u0438\u0437\u0438\u0440\u0443\u0435\u0442\u0441\u044F \u0438/\u0438\u043B\u0438 \u0432\u044B\u0432\u043E\u0434\u0438\u0442\u0441\u044F \u0438\u0437 \u043E\u0440\u0433\u0430\u043D\u0438\u0437\u043C\u0430, \u0441\u0432\u044F\u0437\u0430\u043D\u043D\u0430\u044F \u0447\u0430\u0441\u0442\u044C \u0431\u0443\u0434\u0435\u0442 \u0432\u044B\u0441\u0432\u043E\u0431\u043E\u0436\u0434\u0430\u0442\u044C\u0441\u044F \u0434\u043B\u044F \u043F\u043E\u0434\u0434\u0435\u0440\u0436\u0430\u043D\u0438\u044F \u0440\u0430\u0432\u043D\u043E\u0432\u0435\u0441\u0438\u044F. \u0422\u0430\u043A \u043A\u0430\u043A \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D \u044F\u0432\u043B\u044F\u0435\u0442\u0441\u044F \u043E\u0441\u043D\u043E\u0432\u0430\u043D\u0438\u0435\u043C, \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u044B \u0441 \u043A\u0438\u0441\u043B\u043E\u0439 \u0438 \u043D\u0435\u0439\u0442\u0440\u0430\u043B\u044C\u043D\u043E\u0439 \u0440\u0435\u0430\u043A\u0446\u0438\u0435\u0439 \u0432 \u043F\u0435\u0440\u0432\u0443\u044E \u043E\u0447\u0435\u0440\u0435\u0434\u044C \u0431\u0443\u0434\u0443\u0442 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u0435\u0442\u0441\u044F \u0441 \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D\u043E\u043C. \u0415\u0441\u043B\u0438 \u0444\u0440\u0430\u043A\u0446\u0438\u044F \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D\u043E\u0432 \u0441\u0442\u0430\u043D\u043E\u0432\u0438\u0442\u0441\u044F \u043D\u0430\u0441\u044B\u0449\u0435\u043D\u043D\u043E\u0439, \u0442\u043E \u044D\u0442\u043E\u0442 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u0435\u0442\u0441\u044F \u0441 \u043B\u0438\u043F\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u0430\u043C\u0438. \u041E\u0441\u043D\u043E\u0432\u043D\u044B\u0435 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u044B \u0441\u0432\u044F\u0437\u044B\u0432\u0430\u044E\u0442\u0441\u044F \u0441 \u043A\u0438\u0441\u043B\u044B\u043C \u0430\u043B\u044C\u0444\u0430-1-\u043A\u0438\u0441\u043B\u044B\u043C \u0433\u043B\u0438\u043A\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u043E\u043C. \u042D\u0442\u043E \u0432\u0430\u0436\u043D\u043E, \u043F\u043E\u0441\u043A\u043E\u043B\u044C\u043A\u0443 \u0440\u0430\u0437\u043B\u0438\u0447\u043D\u044B\u0435 \u0443\u0441\u043B\u043E\u0432\u0438\u044F \u043C\u043E\u0433\u0443\u0442 \u0432\u043B\u0438\u044F\u0442\u044C \u043D\u0430 \u0443\u0440\u043E\u0432\u0435\u043D\u044C \u0432 \u043F\u043B\u0430\u0437\u043C\u0435 \u0430\u043B\u044C\u0431\u0443\u043C\u0438\u043D\u0430, \u0430\u043B\u044C\u0444\u0430-1-\u043A\u0438\u0441\u043B\u044B\u0439 \u0433\u043B\u0438\u043A\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D, \u0438 \u043B\u0438\u043F\u043E\u043F\u0440\u043E\u0442\u0435\u0438\u043D\u043E\u0432."@ru ,
"Plasma protein binding refers to the degree to which medications attach to proteins within the blood. A drug's efficiency may be affected by the degree to which it binds. The less bound a drug is, the more efficiently it can traverse or diffuse through cell membranes. Common blood proteins that drugs bind to are human serum albumin, lipoprotein, glycoprotein, and \u03B1, \u03B2\u201A and \u03B3 globulins."@en ,
"\u5927\u591A\u6570\u836F\u7269\u53EF\u4EE5\u4E0E\u8840\u6D46\u4E2D\u7684\u86CB\u767D\u8D28(\u5982\u4EBA\u8840\u6E05\u767D\u86CB\u767D\u3001\u8102\u86CB\u767D\u3001\u7CD6\u86CB\u767D\u548C\u03B1, \u03B2, \u03B3 \u7403\u86CB\u767D)\u53D1\u751F\u4E0D\u540C\u7A0B\u5EA6\u7684\u7ED3\u5408\u3002\u5F31\u9178\u6027\u836F\u7269\u4E3B\u8981\u4E0E\u767D\u86CB\u767D\u7ED3\u5408\uFF0C\u5F31\u78B1\u6027\u836F\u7269\u9664\u4E86\u4E0E\u767D\u86CB\u767D\u7ED3\u5408\u5916\uFF0C\u8FD8\u5E38\u4E0E\u8102\u86CB\u767D\u3001\u9178\u6027\u7CD6\u86CB\u767D\u7ED3\u5408\u3002 \u836F\u7269\u4E0E\u8840\u6D46\u86CB\u767D\u7684\u7ED3\u5408\u5F71\u54CD\u836F\u7269\u7684\u6269\u6563\u901F\u5EA6\u3001\u8F6C\u8FD0\u901F\u5EA6\u3001\u4F5C\u7528\u5F3A\u5EA6\u548C\u6D88\u9664\u901F\u7387\u3002 \u836F\u7269\u4E0E\u8840\u6D46\u86CB\u767D\u7684\u7ED3\u5408\u4F53(\u53C8\u79F0)\u4E0D\u80FD\u7A7F\u8FC7\u8840\u7BA1\u5185\u76AE\u7EC6\u80DE\uFF0C\u4E0D\u80FD\u53D1\u6325\u836F\u6548\uFF0C\u56E0\u6B64\u8FD9\u79CD\u7ED3\u5408\u6210\u4E3A\u836F\u7269\u5728\u8840\u6DB2\u4E2D\u7684\u4E00\u79CD\u6682\u65F6\u8D2E\u5B58\u5F62\u5F0F\u3002\u53C8\u56E0\u4E3A\u8FD9\u79CD\u7ED3\u5408\u662F\u53EF\u9006\u7684\uFF0C\u5F53\u8840\u6D46\u4E2D\u6E38\u79BB\u578B\u7684\u836F\u7269\u56E0\u6269\u6563\u3001\u6E05\u9664\u800C\u6D53\u5EA6\u964D\u4F4E\u65F6\uFF0C\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7684\u836F\u7269\u5C31\u4F1A\u6E38\u79BB\u51FA\u6765\uFF0C\u6269\u6563\u5165\u7EC4\u7EC7\u4E2D\u53D1\u6325\u836F\u6548\u3002\u53C8\u56E0\u4E3A\u8FD9\u79CD\u7ED3\u5408\u6CA1\u6709\u7279\u5F02\u6027\uFF0C\u5F53\u4E24\u79CD\u836F\u7269\u5B58\u5728\u4E8E\u8840\u6DB2\u4E2D\u65F6\uFF0C\u4E24\u8005\u53EF\u56E0\u7ADE\u4E89\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7684\u4F4D\u7F6E\uFF0C\u63D0\u9AD8\u836F\u7269\u5728\u8840\u6D46\u4E2D\u7684\u6E38\u79BB\u6D53\u5EA6\uFF0C\u52A0\u901F\u5176\u6269\u6563\uFF0C\u63D0\u9AD8\u5176\u836F\u6548\uFF0C\u540C\u65F6\u52A0\u91CD\u5176\u526F\u4F5C\u7528\u3002 \u4E00\u822C\u8BA4\u4E3A\uFF0C\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u7387\u9AD8\u3001\u5206\u5E03\u5BB9\u79EF\u5C0F\u3001\u6D88\u9664\u6162\u3001\u6CBB\u7597\u6307\u6570\u4F4E\u7684\u836F\u7269\uFF0C\u5BB9\u6613\u51FA\u73B0\u4E0A\u8FF0\u7684\u836F\u7269\u76F8\u4E92\u4F5C\u7528\u3002 \u6BD4\u5982\u6297\u51DD\u8840\u836F\u534E\u6CD5\u6797(warfarin)99%\u4E0E\u8840\u6D46\u86CB\u767D\u7ED3\u5408\uFF0C\u5F53\u5B83\u4E0E\u4FDD\u6CF0\u677E(\uFF0C\u8840\u6D46\u86CB\u767D\u7ED3\u5408\u738798%)\u5408\u7528\u65F6\uFF0C\u7ED3\u5408\u7684\u534E\u6CD5\u6797\u4F1A\u88AB\u7F6E\u6362\u51FA\u6765\uFF0C\u6E38\u79BB\u578B\u7684\u534E\u6CD5\u6797\u6D53\u5EA6\u5347\u9AD8\uFF0C\u52A0\u5F3A\uFF0C\u52A0\u91CD\uFF0C\u60A3\u8005\u53EF\u56E0\u4E25\u91CD\u51FA\u8840\u800C\u6B7B\u4EA1\u3002"@zh ,
"Ikatan protein plasma merujuk pada sejauh mana sebuah obat terikat pada protein di dalam darah. Semakin sedikit ikatan suatu obat, semakin efisien obat tersebut dapat melintasi membran sel atau berdifusi. Protein di dalam darah yang mengikat obat antara lain albumin serum, lipoprotein, glikoprotein, dan globulin alfa, beta, serta gamma."@in ,
"As drogas sofrem liga\u00E7\u00E3o a prote\u00EDnas plasm\u00E1ticas. A efic\u00E1cia de uma droga \u00E9 afetada pelo grau em que ela se liga a prote\u00EDnas no plasma sangu\u00EDneo. Quanto menos ligante a droga for, mais eficientemente ela pode transpor as membranas celular ou se difundir. As prote\u00EDnas em que as drogas mais se ligam s\u00E3o a albumina, lipoprote\u00EDna, glicoprote\u00EDna e globulinas \u03B1, \u00DF\u201A e \u03B3. Uma droga existe no sangue em duas formas: ligada e n\u00E3o ligada a prote\u00EDnas. Dependendo da afinidade da droga espec\u00EDfica pela prote\u00EDna plasm\u00E1tica, uma por\u00E7\u00E3o da droga pode se tornar ligada \u00E0s prote\u00EDnas plasm\u00E1ticas, enquanto o restante permanece n\u00E3o-ligado. Se a liga\u00E7\u00E3o \u00E0 prote\u00EDna \u00E9 revers\u00EDvel, ent\u00E3o um equil\u00EDbrio qu\u00EDmico ir\u00E1 existir entre os estados ligado e n\u00E3o-ligados, tal que: prote\u00EDna + droga \u21CC complexo prote\u00EDna-droga Notavelmente, \u00E9 a fra\u00E7\u00E3o n\u00E3o-ligada (ou livre) que exibe efeitos farmacol\u00F3gicos. \u00C9 tamb\u00E9m a fra\u00E7\u00E3o que pode ser metabolizada e/ou excretada. Por exemplo, a \"fra\u00E7\u00E3o ligante\" do anticoagulante varfarina \u00E9 de 97%. Isso significa que 97% de toda varfarina presente no sangue est\u00E1 ligada a prote\u00EDnas plasm\u00E1ticas. Os 3% restantes (fra\u00E7\u00E3o n\u00E3o-ligada) s\u00E3o a fra\u00E7\u00E3o que est\u00E1 realmente ativa e pode ser excretada. A liga\u00E7\u00E3o a prote\u00EDnas pode influenciar na meia-vida biol\u00F3gica no corpo. A por\u00E7\u00E3o ligada pode atuar como um reservat\u00F3rio ou dep\u00F3sito do qual a droga \u00E9 lentamente liberada na forma n\u00E3o-ligada. Como a forma n\u00E3o-ligada est\u00E1 sendo metabolizada e/ou excretada do corpo, a fra\u00E7\u00E3o ligada ser\u00E1 liberada a fim de que se mantenha o equil\u00EDbrio. J\u00E1 que a albumina \u00E9 b\u00E1sica, drogas neutras e \u00E1cidas ir\u00E3o primariamente se ligar a ela. Se a albumina se tornar saturada, estas drogas ir\u00E3o se ligar ent\u00E3o \u00E0 lipoprote\u00EDna. Drogas b\u00E1sicas ir\u00E3o se ligar \u00E0 alfa-1-glicoprote\u00EDna \u00E1cida. Isto \u00E9 importante, pois v\u00E1rias condi\u00E7\u00F5es m\u00E9dicas afetam os n\u00EDveis de albumina, alfa-1-glicoprote\u00EDna \u00E1cida e lipoprote\u00EDna."@pt ,
"La eficacia de un f\u00E1rmaco puede ser afectada por el grado de uni\u00F3n a las prote\u00EDnas dentro del plasma sangu\u00EDneo. La m\u00EDnima parte unida de un f\u00E1rmaco puede atravesar de manera eficiente las membranas celulares o difundirse. Las prote\u00EDnas comunes a las cuales se une un f\u00E1rmaco son la alb\u00FAmina s\u00E9rica humana, las lipoprote\u00EDnas, glicoprote\u00EDnas \u03B1, \u00DF\u201A y a las \u03B3 globulinas. Un f\u00E1rmaco en la sangre existe en dos formas: ligado o libre. Dependiendo de la afinidad espec\u00EDfica del f\u00E1rmaco con el plasma, una proporci\u00F3n del mismo puede unirse a las prote\u00EDnas del plasma y el resto quedar libre, si la interacci\u00F3n molecular prote\u00EDnica es reversible, entonces existir\u00E1 un equilibrio qu\u00EDmico entre los estados libre y ligado, tal: Prote\u00EDna + f\u00E1rmaco \u21CC Complejo F\u00E1rmaco-Prote\u00EDna Notablemente, es la fracci\u00F3n libre la que exhibe los efectos farmacol\u00F3gicos. Es tambi\u00E9n la proporci\u00F3n libre la que puede ser metabolizada o excretada. Por ejemplo la fracci\u00F3n l\u00EDmite del anticoagulante warfarina es un 97%. Esto significa que la cantidad de warfarina en la sangre un 97% est\u00E1 unida a las prote\u00EDnas del plasma. El remanente 3% es la cantidad activa y que puede ser excretada. La uni\u00F3n prote\u00EDnica puede influir en la vida media de eliminaci\u00F3n en el cuerpo. La proporci\u00F3n ligada puede actuar como un dep\u00F3sito o reserva del f\u00E1rmaco que es liberado lentamente como proporci\u00F3n libre. Mientras que la parte libre es metabolizada o excretada del cuerpo, la proporci\u00F3n ligada ser\u00E1 liberada a fin de mantener el equilibrio. Dado que la alb\u00FAmina es ligeramente b\u00E1sica, los f\u00E1rmacos \u00E1cidos o neutrales se unir\u00E1n primariamente a ella. Si la alb\u00FAmina se satura , entonces los f\u00E1rmacos se unir\u00E1n a las lipoprote\u00EDnas. Los f\u00E1rmacos de perfil b\u00E1sico se unir\u00E1n a la \u00E1cida alfa-1 glicoprote\u00EDna \u00E1cida. Esto es relevante ya que diversas condiciones m\u00E9dicas pueden afectar los niveles de albumina, alfa-1 glicoprote\u00EDna \u00E1cida y lipoprote\u00EDnas."@es ,
"\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u7D50\u5408\uFF08\u3051\u3063\u3057\u3087\u3046\u30BF\u30F3\u30D1\u30AF\u3051\u3064\u3054\u3046\uFF09\u306F\u3001\u85AC\u7269\u3068\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u306E\u9593\u306E\u7D50\u5408\u3002 \u85AC\u7269\u306E\u52B9\u679C\u306F\u3001\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u3057\u3084\u3059\u3055\u306B\u5F71\u97FF\u3092\u53D7\u3051\u308B\u3002\u3088\u308A\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u304C\u5F31\u3044\u85AC\u7269\u306F\u3088\u308A\u52B9\u7387\u3088\u304F\u7D30\u80DE\u819C\u3092\u900F\u904E\u3057\u7D44\u7E54\u4E2D\u306B\u62E1\u6563\u3059\u308B\u3002\u85AC\u7269\u3068\u7D50\u5408\u3092\u6210\u3059\u4EE3\u8868\u7684\u306A\u8840\u4E2D\u30BF\u30F3\u30D1\u30AF\u8CEA\u306B\u306F\u8840\u6E05\u30A2\u30EB\u30D6\u30DF\u30F3\u3001\u30EA\u30DD\u30BF\u30F3\u30D1\u30AF\u8CEA\u3001\u7CD6\u30BF\u30F3\u30D1\u30AF\u8CEA\u3001\u3068\u03B1\u3001\u03B2\u3001\u03B3\u306E\u5404\u30B0\u30ED\u30D6\u30EA\u30F3\u3067\u3042\u308B\u3002 \u85AC\u7269\u306F\u8840\u4E2D\u3067\u306F\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u306B\u7D50\u5408\u3057\u3066\u3044\u308B\u7D50\u5408\u578B\u3001\u7D50\u5408\u3057\u3066\u3044\u306A\u3044\u975E\u7D50\u5408\u578B\u306E\u4E8C\u3064\u306E\u72B6\u614B\u3067\u5B58\u5728\u3059\u308B\u3002\u7D50\u5408\u578B\u3068\u975E\u7D50\u5408\u578B\u306E\u5B58\u5728\u6BD4\u7387\u306F\u3001\u901A\u5E38\u306F\u5404\u85AC\u7269\u306B\u56FA\u6709\u306A\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u89AA\u548C\u6027\u306B\u3088\u308A\u6C7A\u5B9A\u3055\u308C\u308B\u3002\u307B\u3068\u3093\u3069\u306E\u533B\u85AC\u54C1\u306F\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u306E\u7D50\u5408\u304C\u53EF\u9006\u3067\u3042\u308A\u3001\u4EE5\u4E0B\u306E\u3088\u3046\u306A\u5316\u5B66\u5E73\u8861\u304C\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\uFF08P\uFF09\u3001\u7D50\u5408\u578B\uFF08PD complex\uFF09\u3001\u975E\u7D50\u5408\u578B\uFF08D\uFF09\u306E\u9593\u306B\u6210\u308A\u7ACB\u3064\u3002 \u591A\u304F\u306E\u5834\u5408\u3001\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u85AC\u7269\u3068\u306E\u7D50\u5408\u305D\u306E\u3082\u306E\u306F\u5F31\u304F\u3001\u7D50\u5408\u3068\u89E3\u96E2\u306E\u901F\u5EA6\u304C\u6975\u3081\u3066\u901F\u3044\u3002\u3057\u305F\u304C\u3063\u3066\u5168\u4F53\u3067\u306F\u4E00\u5B9A\u306E\u6BD4\u7387\u3092\u4FDD\u3061\u306A\u304C\u3089\u3082\u500B\u3005\u306E\u85AC\u7269\u5206\u5B50\u306F\u7D50\u5408\u578B\u3068\u975E\u7D50\u5408\u578B\u3092\u7D20\u65E9\u304F\u884C\u304D\u6765\u3057\u3066\u3044\u308B\u3068\u898B\u306A\u3059\u3079\u304D\u3067\u3042\u308B\u3002\u7D50\u5408\u578B\u306F\u7D30\u80DE\u819C\u3092\u900F\u904E\u3057\u306A\u3044\u306E\u3067\u3001\u85AC\u5B66\u7684\u52B9\u679C\u3092\u793A\u3059\u306E\u306F\u975E\u7D50\u5408\u578B\u3067\u3042\u308B\u3002\u307E\u305F\u4E3B\u306B\u4EE3\u8B1D\u3084\u6392\u51FA\u4F5C\u7528\u3092\u53D7\u3051\u308B\u306E\u3082\u975E\u7D50\u5408\u578B\u3067\u3042\u308B\u3002\u305F\u3068\u3048\u3070\u3001\u6297\u51DD\u56FA\u5264\u30EF\u30EB\u30D5\u30A1\u30EA\u30F3\u306E\u7D50\u5408\u7387\u306F97%\u3067\u3042\u308B\u3002\u3053\u308C\u306F\u8840\u4E2D\u3067\u306F\u30EF\u30EB\u30D5\u30A1\u30EA\u30F3\u306F\u7DCF\u91CF\u306E97%\u304C\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u7D50\u5408\u3057\u3066\u3044\u308B\u3053\u3068\u3092\u610F\u5473\u3057\u3001\u6B8B\u308A\u306E3%\u304C\u7D30\u80DE\u5185\u3078\u3068\u62E1\u6563\u3057\u6D3B\u6027\u3092\u793A\u3059\u304B\u3001\u4EE3\u8B1D\u3055\u308C\u6392\u51FA\u3092\u53D7\u3051\u308B\u5BFE\u8C61\u3068\u306A\u308B\u3002\u540C\u69D8\u306E\u7406\u7531\u3067\u85AC\u7269\u306E\u4F53\u5185\u3067\u306E\u534A\u6E1B\u671F\u306F\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u7D50\u5408\u306E\u3057\u3084\u3059\u3055\u306B\u5F71\u97FF\u3055\u308C\u308B\u3002\u7D50\u5408\u578B\u306F\u85AC\u7269\u304C\u975E\u7D50\u5408\u578B\u3068\u3057\u3066\u3086\u3063\u304F\u308A\u3068\u653E\u51FA\u3055\u308C\u3066\u3086\u304F\u8CAF\u8535\u7269\u3084\u4F9B\u7D66\u7269\u3068\u3057\u3066\u3075\u308B\u307E\u3046\u3002\u975E\u7D50\u5408\u578B\u306F\u4EE3\u8B1D\u3084\u6392\u51FA\u4F5C\u7528\u306B\u3088\u308A\u9010\u6B21\u6E1B\u5C11\u3057\u3066\u3086\u304F\u306E\u3067\u3001\u5E73\u8861\u3092\u4FDD\u3064\u305F\u3081\u7D50\u5408\u578B\u304C\u975E\u7D50\u5408\u578B\u306B\u5909\u5316\u3059\u308B\u305F\u3081\u3067\u3042\u308B\u3002\u4E0A\u8FF0\u306E\u3088\u3046\u306B\u3001\u5E73\u8861\u306E\u901F\u5EA6\u306F\u5341\u5206\u901F\u3044\u306E\u3067\u85AC\u7269\u306E\u7DCF\u91CF\u304C\u6E1B\u5C11\u3057\u3066\u3082\u7D50\u5408\u578B\u3068\u975E\u7D50\u5408\u578B\u306E\u6BD4\u7387\u306F\u5909\u5316\u3057\u306A\u3044\u3002\u30A2\u30EB\u30D6\u30DF\u30F3\u306F\u5869\u57FA\u6027\u3067\u3042\u308B\u305F\u3081\u9178\u6027\u307E\u305F\u306F\u4E2D\u6027\u306E\u85AC\u7269\u306F\u307E\u305A\u30A2\u30EB\u30D6\u30DF\u30F3\u3068\u7D50\u5408\u3059\u308B\u3002\u30A2\u30EB\u30D6\u30DF\u30F3\u304C\u98FD\u548C\u3059\u308B\u3068\u6B21\u306B\u30EA\u30DD\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u7D50\u5408\u3059\u308B\u3002\u5869\u57FA\u6027\u85AC\u7269\u306F\u9178\u6027\u306E\u30D2\u30C8\u8840\u6F3F\u03B11\u9178\u6027\u7CD6\u30BF\u30F3\u30D1\u30AF\u8CEA\uFF08AGP\u3001\u30AA\u30ED\u30BD\u30E0\u30B3\u30A4\u30C9\uFF09\u3068\u30EA\u30DD\u30BF\u30F3\u30D1\u30AF\u8CEA\u3068\u7D50\u5408\u3059\u308B\u3002\u500B\u4F53\u306E\u75C5\u72B6\u306B\u3088\u308A\u30A2\u30EB\u30D6\u30DF\u30F3\u3001\u03B11\u7CD6\u30BF\u30F3\u30D1\u30AF\u8CEA\u3001\u30EA\u30DD\u30BF\u30F3\u30D1\u30AF\u8CEA\u306E\u8840\u4E2D\u6FC3\u5EA6\u306F\u7570\u306A\u308B\u3053\u3068\u304C\u3042\u308A\u3001\u540C\u3058\u6295\u4E0E\u91CF\u3067\u3082\u52B9\u679C\u304C\u7570\u306A\u308B\u53EF\u80FD\u6027\u304C\u3042\u308B\u3002\u5B9F\u969B\u306B\u306F\u8840\u6F3F\u4E2D\u306E\u85AC\u7269\u6FC3\u5EA6\u3092\u6E2C\u5B9A\u3057\u3066\u7D50\u5408\u7387\u3092\u6C7A\u5B9A\u3059\u308B\u3002\u975E\u7D50\u5408\u578B\u306E\u6BD4\u7387\u306F\u4F53\u5185\u306E\u85AC\u7269\u91CF\u3001\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u306E\u8CEA\u3068\u91CF\u3001\u4ED6\u306E\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u3068\u7D50\u5408\u3057\u3046\u308B\u85AC\u7269\u306A\u3069\u306B\u5F71\u97FF\u3055\u308C\u308B\u3002\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u304C\u85AC\u7269\u3067\u98FD\u548C\u3059\u308B\u3068\u3001\u305D\u306E\u6642\u70B9\u304B\u3089\u306F\u3001\u3088\u308A\u9AD8\u3044\u85AC\u7269\u6FC3\u5EA6\u306F\u975E\u7D50\u5408\u578B\u306E\u6BD4\u7387\u3092\u9AD8\u3081\u308B\u3002\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u306E\u91CF\u304C\u4F55\u3089\u304B\u306E\u539F\u56E0\u3067\u6E1B\u5C11\u3059\u308B\u3068\uFF08\u7570\u5316\u4F5C\u7528\u3001\u6804\u990A\u5931\u8ABF\u3001\u809D\u81D3\u3084\u814E\u81D3\u306E\u6A5F\u80FD\u969C\u5BB3\u306A\u3069\uFF09\u3084\u306F\u308A\u975E\u7D50\u5408\u578B\u304C\u5897\u52A0\u3059\u308B\u3002\u52A0\u3048\u3066\u8840\u6F3F\u30BF\u30F3\u30D1\u30AF\u306E\u8CEA\u3082\u30BF\u30F3\u30D1\u30AF\u8CEA\u4E0A\u306E\u7D50\u5408\u90E8\u4F4D\u306E\u6570\u306B\u5F71\u97FF\u3059\u308B\u3053\u3068\u304C\u3042\u308B\u3002"@ja ,
"Il legame dei farmaci alle proteine plasmatiche \u00E8 il parametro farmacocinetico pi\u00F9 importante nel determinare la ripartizione di un farmaco dal sangue ai tessuti.Tale fenomeno consiste nella creazione di legami deboli e reversibili tra un farmaco e uno specifico sito di una proteina plasmatica."@it ,
"De plasma-eiwitbinding is het gedeelte van een geneesmiddel of lichaamseigen stof dat aan plasma-eiwitten in het bloed is gebonden. Toegediende geneesmiddelen kunnen net als lichaamseigen stoffen zoals calcium met de aanwezige plasma-eiwitten een binding aangaan. Er is dan een gedeelte dat is gebonden aan plasma-eiwitten en er is een ongebonden, vrije fractie. Alleen het niet-gebonden gedeelte van het geneesmiddel is farmacologisch actief. Ook bij de omzetting in de lever en bij de eliminatie via de nieren wordt alleen de ongebonden fractie verwerkt. De gebonden fractie vormt zo een soort van reservoir van het geneesmiddel, dat weer vrij kan komen als de binding reversibel is. Van de plasma-eiwitten bestaat ongeveer 70% uit het albumine. Farmacologische relevante effecten van de plasma-eiwitbinding treden pas op als de gebonden fractie boven de 90% komt. Een klassiek voorbeeld is dat van het geneesmiddel fenylbutazon met een bindingspercentage van 98%. Bij een dergelijk hoog bindingspercentage is zo\u2019n geneesmiddel in staat om op zijn beurt andere stoffen uit hun plasma-eiwitbinding te verdringen en zo geneesmiddeleninteracties te veroorzaken. Ook kan bij ziektes zoals ondervoeding, leverziekten, en nierziekte de plasma-eiwitbinding verlaagd zijn omdat er minder plasma-eiwitten beschikbaar zijn. De vrije fractie van het geneesmiddel is dan groter dan normaal te verwachten is en een sterk gebonden geneesmiddel werkt dan extra sterk."@nl ,
"Als Proteinbindung, auch Plasmaproteinbindung (PPB) oder Plasmaeiwei\u00DFbindung (PEB) genannt, wird die reversible Bindung von Stoffen an Eiwei\u00DFbestandteile des Blutes (Plasmaproteine, Erythrozytenproteine) oder der K\u00F6rpergewebe bezeichnet. An dieser Proteinbindung k\u00F6nnen verschiedene Formen chemischer Bindungen beteiligt sein, namentlich ionische Bindungen, Wasserstoffbr\u00FCckenbindungen, Dipol-Dipol-Wechselwirkungen sowie hydrophobe Wechselwirkungen. Die Proteinbindung hat zur Folge, dass die gebundenen Stoffe, unter anderem Arzneimittel und verschiedene k\u00F6rpereigene Substanzen, ihre normale Wirkung nicht oder nur vermindert aus\u00FCben, da sie nicht wie sonst mit der Umgebung reagieren k\u00F6nnen. Der durch Proteine gebundene Anteil eines Stoffes ist somit pharmakologisch inaktiv. Kleine Molek\u00FCle erlangen durch die Bindung eine stark verl\u00E4ngerte Halbwertszeit, werden also nur sehr verlangsamt \u00FCber die Niere ausgeschieden. Zu den Substanzen, die zu einem gro\u00DFen Teil im Plasma an Proteine gebunden sind, geh\u00F6ren beispielsweise die Arzneistoffe Sulfonamide, Sulfonylharnstoffe, Acetylsalicyls\u00E4ure, Phenylbutazon, Cumarine sowie die k\u00F6rpereigenen Stoffe Bilirubin und Calcium. Die Gesamtmenge eines Stoffes, die gebunden werden kann, ist durch die Kapazit\u00E4t der Proteine begrenzt. Durch gegenseitige Verdr\u00E4ngung aus der Plasmaproteinbindung k\u00F6nnen Substanzen wechselseitig ihre effektiv wirksame (da nicht gebundene) Konzentration im Blut steigern (Synergismus). Aus diesem Grund verst\u00E4rken zum Beispiel Sulfonamide den Neugeborenenikterus durch Verdr\u00E4ngung des Bilirubins vom Albumin und sind daher bei Neugeborenen kontraindiziert. Bei Gabe verschiedener Arzneistoffe k\u00F6nnen auf diesem Prinzip basierende Arzneimittelwechselwirkungen zum Auftreten von unerw\u00FCnschten Arzneimittelwirkungen (Nebenwirkungen) f\u00FChren. Dieser Artikel behandelt ein Gesundheitsthema. Er dient nicht der Selbstdiagnose und ersetzt nicht eine Diagnose durch einen Arzt. Bitte hierzu den Hinweis zu Gesundheitsthemen beachten!"@de ,
"\u0627\u0644\u0631\u0628\u0637 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u064A \u0644\u0647 \u0623\u0647\u0645\u064A\u0629 \u0641\u064A \u0639\u0644\u0648\u0645 \u0627\u0644\u0635\u064A\u062F\u0644\u0629 \u0648\u0627\u0644\u0637\u0628\u060C \u0641\u0642\u062F \u062A\u062A\u0623\u062B\u0631 \u0643\u0641\u0627\u0621\u0629 \u0627\u0644\u062F\u0648\u0627\u0621 \u0628\u0627\u0644\u062F\u0631\u062C\u0629 \u0627\u0644\u062A\u064A \u062A\u062A\u0631\u0628\u0637 \u0628\u0647\u0627 \u0628\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0628\u0644\u0627\u0632\u0645\u0627 \u0627\u0644\u062F\u0645. \u0623\u0642\u0644 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0631\u062A\u0628\u0627\u0637\u0627\u064B \u0628\u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0647\u064A \u0623\u0643\u062B\u0631\u0647\u0627 \u0643\u0641\u0627\u0621\u0629 \u0648\u064A\u0645\u0643\u0646\u0647\u0627 \u0623\u0646 \u062A\u0639\u0628\u0631 \u0627\u0644\u0623\u063A\u0634\u064A\u0629 \u0627\u0644\u062E\u0644\u0648\u064A\u0629 \u0648\u062A\u0646\u062A\u0634\u0631. \u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0627\u0644\u062F\u0645 \u0627\u0644\u0634\u0627\u0626\u0639\u0629 \u0627\u0644\u062A\u064A \u062A\u0631\u062A\u0628\u0637 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0628\u0647\u0627 \u0647\u064A: \n* \u0623\u0644\u0628\u064A\u0648\u0645\u064A\u0646 \u0627\u0644\u0645\u0635\u0644 \u0627\u0644\u0628\u0634\u0631\u064A \n* \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u062F\u0647\u0646\u064A \n* \u0628\u0631\u0648\u062A\u064A\u0646 \u0633\u0643\u0631\u064A \n* \u063A\u0644\u0648\u0628\u0648\u0644\u064A\u0646 \n* \n* \n* \n* \u063A\u0644\u0648\u0628\u064A\u0648\u0644\u064A\u0646 \u063A\u0627\u0645\u0627 \u062A\u062A\u0648\u0627\u062C\u062F \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0641\u064A \u0627\u0644\u062F\u0645 \u0641\u064A \u0634\u0643\u0644\u064A\u0646: \u0645\u0631\u062A\u0628\u0637\u0629 \u0648\u063A\u064A\u0631 \u0645\u0631\u062A\u0628\u0637\u0629. \u0648\u064A\u0639\u062A\u0645\u062F \u062A\u0642\u0627\u0631\u0628 \u062F\u0648\u0627\u0621 \u0645\u0639\u064A\u0646 \u0645\u0639 \u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u0628\u0644\u0627\u0632\u0645\u0627 \u0641\u064A \u0627\u0644\u0645\u0648\u0627\u0635\u0641\u0627\u062A\u060C \u0641\u0642\u062F \u062A\u0648\u062C\u062F \u0646\u0633\u0628\u0629 \u0645\u0646 \u0627\u0644\u062F\u0648\u0627\u0621 \u0645\u0631\u062A\u0628\u0637\u0629 \u0628\u0628\u0631\u0648\u062A\u064A\u0646\u0627\u062A \u0627\u0644\u0628\u0644\u0627\u0632\u0645\u0627\u060C \u0641\u064A\u0645\u0627 \u062A\u0628\u0642\u0649 \u0627\u0644\u0646\u0633\u0628\u0629 \u0627\u0644\u0628\u0627\u0642\u064A\u0629 \u063A\u064A\u0631 \u0645\u0631\u062A\u0628\u0637\u0629. \u0648\u0625\u0630\u0627 \u0643\u0627\u0646 \u0627\u0644\u0631\u0628\u0637 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646\u064A \u0639\u0643\u0633\u064A\u0627\u064B\u060C \u0641\u0633\u064A\u062D\u0635\u0644 \u0627\u0644\u062A\u0648\u0627\u0632\u0646 \u0627\u0644\u0643\u064A\u0645\u064A\u0627\u0626\u064A \u0643\u0645\u0627 \u064A\u0644\u064A: \u0628\u0631\u0648\u062A\u064A\u0646 + \u062F\u0648\u0627\u0621 \u21CC \u0645\u0639\u0642\u062F \u0628\u0631\u0648\u062A\u064A\u0646-\u062F\u0648\u0627\u0621"@ar ,
"L'efic\u00E0cia d'un f\u00E0rmac pot ser afectada pel grau d'uni\u00F3 a les prote\u00EFnes dins del plasma sanguini. Es tracta de la m\u00EDnima part unida d'un f\u00E0rmac que pot travessar de manera eficient les membranes cel\u00B7lulars o difondre's. Les prote\u00EFnes comunes a les quals s'uneix un f\u00E0rmac s\u00F3n l'alb\u00FAmina serosa humana, les lipoprote\u00EFnes, glicoprote\u00EFnes \u03B1, \u00DF, i les \u03B3 . Un f\u00E0rmac en la sang existeix en dues formes lligat o solt. Depenent de l'afinitat espec\u00EDfica del medicament amb el plasma, una proporci\u00F3 del mateix pot unir-se a les prote\u00EFnes del plasma i la resta quedar lliure, si la prote\u00EDnica \u00E9s reversible, aleshores existir\u00E0 un equilibri qu\u00EDmic entre els estats lliure i lligat, tal: Prote\u00EFna + f\u00E0rmac \u21CC Complex F\u00E0rmac-Prote\u00EFna Notablement, \u00E9s la fracci\u00F3 lliure la que exhibeix els efectes farmacol\u00F2gics. \u00C9s tamb\u00E9 la proporci\u00F3 lliure la que pot ser metabolitzada o excretada. Per exemple la fracci\u00F3 l\u00EDmit de l'anticoagulant warfarina \u00E9s un 97%. Aix\u00F2 significa que la quantitat de Warfarina en la sang un 97% est\u00E0 unida a les prote\u00EFnes del plasma. El romanent 3% \u00E9s la quantitat activa i que pot \u00E9s excretada. La uni\u00F3 prote\u00EDnica pot influir en la vida mitjana d'eliminaci\u00F3 en el cos. La proporci\u00F3 lligada pot actuar com un dip\u00F2sit o reserva del f\u00E0rmac que \u00E9s alliberat lentament com proporci\u00F3 lliure. Mentre que la part lliure \u00E9s metabolitzada o excretada del cos, la proporci\u00F3 lligada ser\u00E0 alliberada a fi de mantenir l'equilibri. At\u00E8s que l'alb\u00FAmina \u00E9s lleugerament b\u00E0sica, els f\u00E0rmacs \u00E0cids o neutrals s'uniran prim\u00E0riament a ella. Si l'alb\u00FAmina es satura, llavors els f\u00E0rmacs s'uniran a les lipoprote\u00EFnes. Els f\u00E0rmacs de perfil b\u00E0sic s'uniran a l'\u00E0cida alfa-1 glicoprote\u00EFna \u00E0cida. Aix\u00F2 \u00E9s rellevant, ja que diverses condicions m\u00E8diques poden afectar els nivells d'alb\u00FAmina, alfa-1 glicoprote\u00EFna \u00E0cida i lipoprote\u00EFnes."@ca ;
dbo:wikiPageWikiLink dbr:Anticoagulant ,
dbr:Liver_disease ,
dbr:Cell_membrane ,
dbr:Medication ,
dbr:Malnutrition ,
dbr:Catabolism ,
dbr:Lipoprotein ,
dbr:Renal_disease ,
dbr:Protein ,
dbr:Blood_proteins ,
dbr:Human_serum_albumin ,
dbr:Orosomucoid ,
dbr:Blood_protein ,
dbc:Biochemistry ,
dbr:Biological_half-life ,
dbr:Plasma_protein ,
dbr:Therapeutic_index ,
dbr:Warfarin ,
dbr:Drug ,
dbr:Pharmacokinetics ,
dbr:Chemical_equilibrium ,
dbr:Phenylbutazone ,
dbr:Glycoprotein ,
dbr:Metabolize ,
dbr:Globulin ,
,
dbc:Pharmacokinetics .
@prefix dbp: .
@prefix dbt: .
dbr:Plasma_protein_binding dbp:wikiPageUsesTemplate dbt:Cite_book ,
dbt:Pharmacology ,
dbt:Citation_needed ,
dbt:Short_description ,
dbt:Reflist ,
dbt:Refimprove ;
dbo:wikiPageRevisionID 1121993541 .
@prefix xsd: .
dbr:Plasma_protein_binding dbo:wikiPageLength "8026"^^xsd:nonNegativeInteger ;
dbo:wikiPageID 6025636 .
@prefix owl: .
dbr:Plasma_protein_binding owl:sameAs ,
.
@prefix dbpedia-it: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-it:Legame_dei_farmaci_alle_proteine_plasmatiche ,
dbr:Plasma_protein_binding ,
,
,
.
@prefix ns12: .
dbr:Plasma_protein_binding owl:sameAs ns12:Pagbubuklod_ng_plasma_ng_protina ,
.
@prefix dbpedia-fi: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-fi:Proteiinisitoutuminen_plasmassa ,
.
@prefix dbpedia-nl: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-nl:Plasma-eiwitbinding .
@prefix dbpedia-id: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-id:Ikatan_protein_plasma .
@prefix dbpedia-sr: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-sr:Vezivanje_za_proteine_plazme .
@prefix dbpedia-de: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-de:Proteinbindung ,
.
@prefix ns18: .
dbr:Plasma_protein_binding owl:sameAs ns18:dwih ,
.
@prefix dbpedia-sl: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-sl:Vezava_na_plazemske_beljakovine ,
.
@prefix dbpedia-sh: .
dbr:Plasma_protein_binding owl:sameAs dbpedia-sh:Vezivanje_za_proteine_plazme ,
.
@prefix wikidata: .
dbr:Plasma_protein_binding owl:sameAs wikidata:Q167149 ,
.
@prefix prov: .
dbr:Plasma_protein_binding prov:wasDerivedFrom ;
foaf:isPrimaryTopicOf wikipedia-en:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Urosaurus_ornatus dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Threohydrobupropion dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Protein-bound dbo:wikiPageWikiLink dbr:Plasma_protein_binding ;
dbo:wikiPageRedirects dbr:Plasma_protein_binding .
dbr:Protein_bound dbo:wikiPageWikiLink dbr:Plasma_protein_binding ;
dbo:wikiPageRedirects dbr:Plasma_protein_binding .
dbr:Fluoxetine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Propranolol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cimetidine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Moxestrol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Gabapentin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Volume_of_distribution dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Basimglurant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Anastrozole dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Pharmacokinetics_of_progesterone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Tianeptine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Allylestrenol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ramelteon dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cyclobenzaprine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Protein_binding dbo:wikiPageWikiLink dbr:Plasma_protein_binding ;
dbo:wikiPageRedirects dbr:Plasma_protein_binding .
dbr:Brivaracetam dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Flutamide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Sertraline dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Rosuvastatin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Tramadol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Ketamine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Finasteride dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Elbasvir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Grazoprevir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:RU-59063 dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Chloramphenicol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Galantamine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Cefovecin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Maropitant dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Dexmedetomidine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
@prefix ns23: .
ns23:megestrol_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Hydroxyprogesterone_caproate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Norelgestromin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Norgestimate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Chlormadinone_acetate dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Domperidone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Mirtazapine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Lisuride dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Docetaxel dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
@prefix ns24: .
ns24:sofosbuvir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Liothyronine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Daclatasvir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Palonosetron dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Telmisartan dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Sofosbuvir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Recombinant_human_parathyroid_hormone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Promegestone dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Velpatasvir dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Estetrol dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Teniposide dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Sultamicillin dbo:wikiPageWikiLink dbr:Plasma_protein_binding .
dbr:Nitrendipine dbo:wikiPageWikiLink dbr:Plasma_protein_binding .